MedTrace Logo

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

NCT02101580 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2020-10-01

No results posted yet for this study

Summary

Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.

Conditions

  • Advanced Pancreatic Cancer

Interventions

DRUG

ADI-PEG 20

Sponsors & Collaborators

  • Polaris Group

    lead INDUSTRY

Principal Investigators

  • Maeve Lowery, MD · Memorial Sloan-Kettering Cancer Center (MSKCC)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-17
Primary Completion
2017-05-05
Completion
2017-10-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02101580 on ClinicalTrials.gov